Health Care [ 9/12 ] | Pharmaceuticals [ 31/73 ]
NASDAQ | Common Stock
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States.
Its lead product candidate is the LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of cataplexy or excessive daytime sleepiness in patients seven years of age and older with narcolepsy.
The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017.
Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin 2, Ireland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 25 | -0.05 Increased by +83.33% | -0.07 Increased by +28.57% |
| Mar 3, 25 | -0.05 Increased by +82.76% | -0.02 Decreased by -150.00% |
| Nov 6, 24 | -0.03 Increased by +93.34% | -0.05 Increased by +45.40% |
| Aug 8, 24 | -0.14 Increased by +83.13% | -0.16 Increased by +12.50% |
| May 8, 24 | -0.30 Increased by +37.50% | -0.21 Decreased by -42.86% |
| Feb 29, 24 | -0.29 Increased by +36.96% | -0.26 Decreased by -11.54% |
| Nov 8, 23 | -0.41 Decreased by -24.24% | -0.37 Decreased by -10.81% |
| Aug 9, 23 | -0.83 Increased by +17.82% | -0.38 Decreased by -118.42% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 25 | 52.51 M Increased by +93.21% | -4.92 M Increased by +82.01% | Decreased by -9.37% Increased by +90.69% |
| Dec 31, 24 | 50.41 M Increased by +159.14% | -5.04 M Increased by +82.48% | Decreased by -10.00% Increased by +93.24% |
| Sep 30, 24 | 50.02 M Increased by +613.22% | -2.63 M Increased by +92.76% | Decreased by -5.25% Increased by +98.99% |
| Jun 30, 24 | 41.50 M Increased by +2.67 K% | -13.82 M Increased by +78.55% | Decreased by -33.30% Increased by +99.23% |
| Mar 31, 24 | 27.18 M Increased by +N/A% | -27.34 M Increased by +11.18% | Decreased by -100.60% Decreased by N/A% |
| Dec 31, 23 | 19.45 M Increased by +N/A% | -28.79 M Decreased by -4.87% | Decreased by -147.98% Decreased by N/A% |
| Sep 30, 23 | 7.01 M Increased by +N/A% | -36.27 M Decreased by -80.06% | Decreased by -517.17% Decreased by N/A% |
| Jun 30, 23 | 1.50 M Increased by +N/A% | -64.43 M Decreased by -1.56% | Decreased by -4.31 K% Decreased by N/A% |